Management of patients who are not candidates for protease inhibitor therapy

Gastroenterology and Hepatology

Volumn 8, Issue 7, 2012, Pages 464-466

  Pockros, Paul J ^a,b,c  

^a Division of Gastroenterology and Hepatology   (United States)

^b SCRIPPS CLINIC   (United States)

^c SCRIPPS TRANSLATIONAL SCIENCE INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOCEPREVIR; CALCINEURIN INHIBITOR; CYCLOSPORIN; DACLATASVIR; EFAVIRENZ; GS 7977; PEGINTERFERON; PROTEINASE INHIBITOR; RIBAVIRIN; RITONAVIR; SIMEPREVIR; TACROLIMUS; TELAPREVIR; UNCLASSIFIED DRUG;

ANEMIA; CYTOPENIA; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG TOLERABILITY; GENOTYPE; GRAFT RECIPIENT; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER TRANSPLANTATION; MIXED INFECTION; NOTE; PATIENT MONITORING; RASH; TREATMENT RESPONSE; VIRUS LOAD;

EID: 84865522069     PISSN: 15547914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (5)

1. Pockros PJ. Drugs in development for chronic hepatitis C: a promising future. Expert Opin Biol Ther. 2011;11:1611-1622.
2. Naggie S, Sulkowski MS. Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals. Gastroenterology. 2012;142:1324-1334.e3.
3. Saxena V, Terrault N. Hepatitis C virus treatment and liver transplantation in the era of new antiviral therapies. Curr Opin Organ Transplant. 2012;17:216-224.
4. Welzel TM, Zeuzem S. Mixing and matching drugs: what makes sense? Clin Liver Dis. 2011;15:657-664.
5. Gane E. Future hepatitis C virus treatment: interferon-sparing combinations. Liver Int. 2011;31(suppl 1):62-67.